Phase 4Recruiting
MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis
An International, Multicentre, Interventional, Randomised, Assessor-blinded Trial to MAXimise the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis
- Sponsor
- Medical University of Vienna (Academic or other)
- Enrollment
- 182 planned
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate
- Ages
- adults, older adults
- Registry
- NCT06649136
Full record on ClinicalTrials.gov
From the registry
The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study. Patients with active rheumatoid arthritis treated with oral methotrexate up to 25 mg weekly will be randomised in 50:50 fashion to receive 25 mg oral vs subcutaneous methotrexate for the period of 24 weeks. In regular visits, patient reported outcomes, clinical disease activity, therapy adherence and diverse established and exploratory biomarkers will be assessed.
Primary outcomes
- CDAI remission (≤2.8) at week 24
History
Primary completion expected
Last registry update
Registered
Started